UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 7, 2004



                           DRAGON PHARMACEUTICAL INC.
             (Exact name of registrant as specified in its charter)


             Florida                       0-27937               65-0142474
             -------                       -------               ----------
(State or Other Jurisdiction of    Commission File Number)      (IRS Employer
       Incorporation)                                        Identification No.)

      1055 Hastings Street, Suite 1900
         Vancouver, British Columbia                        V6E 2E9
         ----------------------------                       -------
   (Address of Principal Executive Offices)               (Zip Code)


                                 (604) 669-8817
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[X]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Item 8.01   Other Events

     The purpose of this current  report on Form 8-K is to disclose  that Dragon
Pharmaceutical  Inc.  issued a press release on December 7, 2004  announcing the
date of  annual  stockholder  meeting  of the  Company  to vote on the  proposed
acquisition  of  Oriental  Wave  Holdings,  Ltd.,  among a series  of  important
proposals. The press release is attached as an exhibit to this Form 8-K.

Item 9.01   Financial Statements and Exhibits

     (c)  Exhibits

          99.1   Press release dated December 7, 2004.


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      DRAGON PHARMACEUTICAL INC.


Date: December 7, 2004                By:    /s/ Matthew Kavanagh
                                             ----------------------------------
                                      Name:  Matthew Kavanagh
                                      Title: Director of Finance and Compliance
                                             (Principal Financial and Accounting
                                             Officer)

<PAGE>
                                                                Exhibit 99.1


                     Date Set for Dragon Stockholder Meeting
                    on Acquisition of Oriental Wave Holdings

Vancouver,  BC- December 7, 2004. - Dragon  Pharmaceutical  Inc.  (OTC BB: DRUG;
TSX:  DDD;  BBSE:  DRP) ("the  Company") is pleased to announce that January 11,
2005 has been set as the date for the annual stockholder  meeting of the Company
to vote on the proposed  acquisition  of Oriental Wave Holdings,  Ltd.,  among a
series of important proposals. The annual meeting of Dragon stockholders will be
held at Dragon's  corporate  offices at Suite 1900,  1055 West Hastings  Street,
Vancouver,  Canada at 10:00 A.M. Pacific Time.

Stockholders  of Dragon of record as of the close of business  on  November  29,
2004 will be entitled to vote at the meeting.  On or about December 8, 2004, the
Company will send to these stockholders a copy of the definitive proxy statement
in connection to the annual meeting.  If the acquisition is approved by a simple
majority of the  outstanding  shares voted at the  meeting,  Dragon and Oriental
Wave  management  teams  currently   anticipate  to  close  the  transaction  by
mid-January 2005.

"We  are  delighted  to  present  this  proposal  and  other  proposals  to  our
shareholders "said Dr. Alexander Wick, President and CEO of Dragon." The Company
and Oriental Wave have worked diligently  together in preparing the document and
addressing  comments from the SEC and other regulatory agencies and are proud to
provide the extensive proxy statement being sent to shareholders. In view of the
bright  future,  the  proposed  acquisition  of Oriental  Wave  merits  positive
considerations  by all Dragon  shareholders.  All  shareholders  should read the
proxy statement carefully."

About Dragon Pharmaceutical Inc.
--------------------------------
Dragon  Pharmaceutical  Inc.  is  an  international  bio-pharmaceutical  company
headquartered in Vancouver,  Canada,  with a GMP production facility in Nanjing,
China.  Dragon's EPO has been  marketed to treat anemia due to renal failure and
surgery  in 9  countries:  China,  India,  Egypt,  Brazil,  Peru,  Ecuador,  the
Dominican   Republic,   Trinidad-Tobago   and  Kosovo.   Additional   regulatory
submissions are in progress  throughout Central and Eastern Europe,  Asia, Latin
America,  the Middle East and Africa and the Company is in the final preparation
to enter the European Union market.

The foregoing  may be deemed to be soliciting  materials of Dragon in connection
with its  definitive  agreement to acquire  Oriental Wave  announced on June 14,
2004.  This  disclosure is being made in connection with Regulation of Takeovers
and Security Holder  Communications  (Release Nos. 33-7760 and 34-42055) adopted
by the SEC and Rule  14a-12  under  the  Securities  Exchange  Act of  1934,  as
amended.  Dragon  shareholders  and  other  investors  are  urged  to  read  the
definitive  proxy  statement that Dragon will file with the SEC and that will be
sent to  shareholders in connection  with the proposed  acquisition,  because it
contains important information about Dragon,  Oriental Wave and related matters.
Dragon and its directors and executive officers may be deemed to be participants
in Dragon's  solicitation of proxies from Dragon shareholders in connection with
the proposed  acquisition.  Information  regarding  the  participants  and their
security  holdings  can be found in the Form  10-KSB  and the  definitive  proxy
statement  to be filed with the SEC,  which will be  available  from the SEC and
Dragon as described below. The definitive proxy statement is available for free,
both on the SEC web site (http://www.sec.gov) and from Dragon as follows:

Garry Wong
Dragon Pharmaceutical, Inc
1900 - 1055 West Hastings Street, Vancouver, British Columbia, V6E 2E9
Telephone: (604) 669-8817 or North American Toll Free: 1-877-388-3784
Fax: (604) 669-4243
Email: ir@dragonbiotech.com
Website: www.dragonpharma.com or www.dragonbiotech.com
[{"type": "8-K", "sequence": "1", "filename": "for120704.txt", "description": "FOR EVENT REPORTING PRESS RELEASE DTD DEC 7, 2004", "secsgml_size_bytes": 7218}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICALS INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "041188865"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 7, 2004

                           DRAGON PHARMACEUTICAL INC.
             (Exact name of registrant as specified in its charter)

             Florida                       0-27937               65-0142474
             -------                       -------               ----------
(State or Other Jurisdiction of    Commission File Number)      (IRS Employer
       Incorporation)                                        Identification No.)

      1055 Hastings Street, Suite 1900
         Vancouver, British Columbia                        V6E 2E9
         ----------------------------                       -------
   (Address of Principal Executive Offices)               (Zip Code)

                                 (604) 669-8817
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[X]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Item 8.01   Other Events

     The purpose of this current  report on Form 8-K is to disclose  that Dragon
Pharmaceutical  Inc.  issued a press release on December 7, 2004  announcing the
date of  annual  stockholder  meeting  of the  Company  to vote on the  proposed
acquisition  of  Oriental  Wave  Holdings,  Ltd.,  among a series  of  important
proposals. The press release is attached as an exhibit to this Form 8-K.

Item 9.01   Financial Statements and Exhibits

     (c)  Exhibits

          99.1   Press release dated December 7, 2004.

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      DRAGON PHARMACEUTICAL INC.

Date: December 7, 2004                By:    /s/ Matthew Kavanagh
                                             ----------------------------------
                                      Name:  Matthew Kavanagh
                                      Title: Director of Finance and Compliance
                                             (Principal Financial and Accounting
                                             Officer)
Exhibit 99.1

                     Date Set for Dragon Stockholder Meeting
                    on Acquisition of Oriental Wave Holdings

Vancouver,  BC- December 7, 2004. - Dragon  Pharmaceutical  Inc.  (OTC BB: DRUG;
TSX:  DDD;  BBSE:  DRP) ("the  Company") is pleased to announce that January 11,
2005 has been set as the date for the annual stockholder  meeting of the Company
to vote on the proposed  acquisition  of Oriental Wave Holdings,  Ltd.,  among a
series of important proposals. The annual meeting of Dragon stockholders will be
held at Dragon's  corporate  offices at Suite 1900,  1055 West Hastings  Street,
Vancouver,  Canada at 10:00 A.M. Pacific Time.

Stockholders  of Dragon of record as of the close of business  on  November  29,
2004 will be entitled to vote at the meeting.  On or about December 8, 2004, the
Company will send to these stockholders a copy of the definitive proxy statement
in connection to the annual meeting.  If the acquisition is approved by a simple
majority of the  outstanding  shares voted at the  meeting,  Dragon and Oriental
Wave  management  teams  currently   anticipate  to  close  the  transaction  by
mid-January 2005.

"We  are  delighted  to  present  this  proposal  and  other  proposals  to  our
shareholders "said Dr. Alexander Wick, President and CEO of Dragon." The Company
and Oriental Wave have worked diligently  together in preparing the document and
addressing  comments from the SEC and other regulatory agencies and are proud to
provide the extensive proxy statement being sent to shareholders. In view of the
bright  future,  the  proposed  acquisition  of Oriental  Wave  merits  positive
considerations  by all Dragon  shareholders.  All  shareholders  should read the
proxy statement carefully."

About Dragon Pharmaceutical Inc.
--------------------------------
Dragon  Pharmaceutical  Inc.  is  an  international  bio-pharmaceutical  company
headquartered in Vancouver,  Canada,  with a GMP production facility in Nanjing,
China.  Dragon's EPO has been  marketed to treat anemia due to renal failure and
surgery  in 9  countries:  China,  India,  Egypt,  Brazil,  Peru,  Ecuador,  the
Dominican   Republic,   Trinidad-Tobago   and  Kosovo.   Additional   regulatory
submissions are in progress  throughout Central and Eastern Europe,  Asia, Latin
America,  the Middle East and Africa and the Company is in the final preparation
to enter the European Union market.

The foregoing  may be deemed to be soliciting  materials of Dragon in connection
with its  definitive  agreement to acquire  Oriental Wave  announced on June 14,
2004.  This  disclosure is being made in connection with Regulation of Takeovers
and Security Holder  Communications  (Release Nos. 33-7760 and 34-42055) adopted
by the SEC and Rule  14a-12  under  the  Securities  Exchange  Act of  1934,  as
amended.  Dragon  shareholders  and  other  investors  are  urged  to  read  the
definitive  proxy  statement that Dragon will file with the SEC and that will be
sent to  shareholders in connection  with the proposed  acquisition,  because it
contains important information about Dragon,  Oriental Wave and related matters.
Dragon and its directors and executive officers may be deemed to be participants
in Dragon's  solicitation of proxies from Dragon shareholders in connection with
the proposed  acquisition.  Information  regarding  the  participants  and their
security  holdings  can be found in the Form  10-KSB  and the  definitive  proxy
statement  to be filed with the SEC,  which will be  available  from the SEC and
Dragon as described below. The definitive proxy statement is available for free,
both on the SEC web site (http://www.sec.gov) and from Dragon as follows:

Garry Wong
Dragon Pharmaceutical, Inc
1900 - 1055 West Hastings Street, Vancouver, British Columbia, V6E 2E9
Telephone: (604) 669-8817 or North American Toll Free: 1-877-388-3784
Fax: (604) 669-4243
Email: ir@dragonbiotech.com
Website: www.dragonpharma.com or www.dragonbiotech.com